Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema
Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
How this was made
The 30-second read
Why it matters
FDA NDA acceptance is a key regulatory step that can improve perceived approval odds and reprice event-risk expectations through the PDUFA date.
Market read
Traders can treat this as a de-risking regulatory milestone and adjust biotech event-risk exposure toward the 2027 PDUFA window.
What to watch
The article provides efficacy/safety highlights but no FDA review outcome; traders should monitor for complete response letters, label scope, and any manufacturing/CMC questions during review.
Background
Pharvaris is seeking approval for Deucrictibant immediate-release capsules as an on-demand oral treatment for hereditary angioedema attacks.
Market effects
Supports sentiment for bradykinin-pathway HAE therapies and oral on-demand alternatives to injectables.
Primarily US regulatory catalyst with potential read-through to European biotech sentiment.
US FDA milestone can influence global investor appetite for rare-disease oral therapeutics.
Counterpoint
NDA acceptance is not approval; investors may fade the move if the FDA requests additional information or if the approval timeline slips.
Key entities
- companyPharvaris N.V.
Late-stage biopharmaceutical company that announced FDA acceptance of its Deucrictibant NDA.
- drugDeucrictibant
Bradykinin B2 receptor antagonist being reviewed for on-demand treatment of HAE attacks.
- regulatorU.S. FDA
Accepted the NDA and set a PDUFA target action date of April 23, 2027.
